patent cliff

Evolution step-up growth trajectory upward trajectory
Pharma

How biosimilar developers are embracing next phase of US market

Although the so-called biosimilar ‘void’ could pose challenges to upcoming biosimilar availability, the opportunity it presents is also immense.
Pharma money pharma money pharma profits Big Pharma sales drug sales

Obesity meds, China drive $2T in projected 2032 drug sales: report

Jun 23, 2026 9:00am
Astellas

Inside Astellas CEO's plan to counter Xtandi's patent cliff

Jun 11, 2026 6:00pm
Illustration of two hands against a blue background one holding a bright yellow and pink alarm clock the other holding a ye

Editor’s Corner: Pharma's slack tightening across pipelines, trust

Feb 9, 2026 3:00am
Narasimhan

Novartis CEO eyes 2026 growth despite record patent cliff

Feb 4, 2026 2:30pm
The Top Line

A closer look at pharma’s top patent losses in 2025

Mar 21, 2025 9:00am